Biodefense

Soligenix Secures Financial Stability Through 2026 to Advance Rare Disease and Biodefense Pipeline

Soligenix Secures Financial Stability Through 2026 to Advance Rare Disease and Biodefense Pipeline

Soligenix has strengthened its financial position with strategic capital initiatives, providing runway through 2026 to advance multiple late-stage therapeutic and vaccine candidates addressing rare diseases and biodefense needs.

November 4, 2025
Soligenix Advances Heat-Stable Ricin Vaccine Amid Global Biothreat Concerns

Soligenix Advances Heat-Stable Ricin Vaccine Amid Global Biothreat Concerns

Soligenix Inc. is progressing with RiVax®, a heat-stable vaccine against ricin toxin, showcasing significant potential in biodefense and public safety.

August 15, 2025